NASDAQ$RLAY
Relay Therapeutics Inc. · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Relay Therapeutics reported Q1 2026 total revenue of $3.0M (-61% YoY) with a net loss of $73.3M, or $(0.41) per share.
For the quarter ended March 31, 2026, Relay Therapeutics posted total revenue of $3.0 million versus $7.7 million from collaboration funding. Net loss was $73.3 million, or $(0.41) per share, compared with a $(77.1) million loss and $(0.41) in Q1 2025. R&D expense was $70.6 million as precision oncology programs including RLY-2608 advanced.
- Total revenue $3.0M; net loss $(73.3)M ($(0.41) EPS).
- R&D $70.6M focused on PI3Kα and other oncology targets.
- Cash runway and pipeline milestones key value drivers.
- Platform-based drug discovery for allosteric inhibitors.
- Collaboration revenue declined as programs shifted stage.
Headline financials
Revenue & EPS history
Relay Therapeutics · Revenue · Quarterly
$3M
Revenue by segment
Relay Therapeutics · $25.2M total across 1 segment · Q3 2023
- License and Other Revenue$25.2M—100.0%
Forward guidance
Relay discusses clinical trial enrollment, partnership options, and cash runway without numeric quarterly guidance.
Tailwinds
- Loss per share stable despite lower collaboration revenue.
- Interest income $5.4M offsets burn.
- Differentiated allosteric oncology platform.
Headwinds
- Minimal revenue; heavy R&D spend.
- Clinical trial and regulatory binary risks.
- Funding needs for late-stage development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+0.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-0.5%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+11.7%
Q4 2025
Best reaction
-19.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | -2.5% | +11.1% | |
| Q4 2025 | +11.7% | +10.8% | +4.8% | |
| Q3 2025 | -7.4% | -5.5% | +17.6% | |
| Q1 2025 | -4.8% | -9.6% | -2.4% | |
| Q4 2024 | -13.3% | -14.9% | -27.5% | |
| Q3 2024 | +3.2% | +3.5% | -22.5% | |
| Q2 2024 | -6.8% | -5.6% | -8.6% | |
| Q1 2024 | +5.7% | +1.2% | -3.8% | |
| Q4 2023 | -4.6% | -1.8% | -25.7% | |
| Q3 2023 | +10.1% | +19.3% | +27.4% | |
| Q2 2023 | +7.8% | +3.5% | -3.2% | |
| Q1 2023 | +0.5% | -5.3% | +2.3% | |
| Q4 2022 | -3.6% | -8.8% | -13.5% | |
| Q3 2022 | -4.3% | -6.8% | -12.4% | |
| Q2 2022 | +3.8% | -1.6% | +31.7% | |
| Q1 2022 | -19.5% | -33.5% | -31.6% | |
| Q4 2021 | +11.5% | +17.4% | +40.1% | |
| Q3 2021 | +1.7% | +0.6% | -19.6% | |
| Q2 2021 | +1.0% | +0.2% | -1.7% | |
| Q1 2021 | +5.7% | +8.5% | +23.9% | |
| Q4 2020 | -2.3% | +2.0% | -13.5% | |
| Q3 2020 | +0.5% | +13.5% | +5.7% | |
| Q2 2020 | +8.0% | +5.3% | +8.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro